Docking: a domesday report

doi:10.1017/CBO9780511730412.009

7 - Docking: a domesday report

from PART II - COMPUTATIONAL CHEMISTRY METHODOLOGY

Published online by Cambridge University Press: 06 July 2010

Martha S. Head

Edited by

Kenneth M. Merz, Jr ,

Dagmar Ringe and

Charles H. Reynolds

Show author details

Kenneth M. Merz, Jr: Affiliation:
University of Florida
Dagmar Ringe: Affiliation:
Brandeis University, Massachusetts
Charles H. Reynolds: Affiliation:
Johnson & Johnson Pharmaceutical Research & Development

Book contents

Get access

Summary

In 1085, most likely from a desire to audit his tax revenues, William the Conqueror commissioned a survey of the land and resources of the country over which he reigned. The results of that survey come down to us in two tomes, the Little Domesday and the Great Domesday, in which were recorded voluminous amounts of data concerning the land, people, buildings, and chattel throughout England. By no means was this a complete record; large swathes of urban England – London, for example – were not included, nor was there any census of church personnel or property. The Little and Great Domesday books accordingly are an odd mix of completeness and incompleteness, leaving out such large parts of English society yet cataloguing to an excruciating level of detail within the areas surveyed.

Similarly, this chapter is a complete yet incomplete survey of the docking and scoring landscape. We do not review the general principles of docking technologies; a sufficient number of such reviews have been published in peer-reviewed journals alone. Nor do we evaluate the state of the art for docking programs and scoring functions; a number of well-regarded and careful evaluations describe the current capabilities and limitations of the technology. Instead, under “Comments on the Theory of Docking” we will make explicit the connections between docking and a theory of noncovalent association.

Information

Type: Chapter
Information: Drug Design
Structure- and Ligand-Based Approaches
, pp. 98 - 119

DOI: https://doi.org/10.1017/CBO9780511730412.009 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

http://www.nationalarchives.gov.uk/domesday/.

Kontoyianni, M.; Madhav, P.; Suchanek, E.; Seibel, W.Theoretical and practical considerations in virtual screening: a beaten field?Curr. Med. Chem. 2008, 15, 107–116.Google Scholar

Cavasotto, C. N.; Orry, A. J. W.Ligand docking and structure-based virtual screening in drug discovery. Curr. Top. Med. Chem. 2007, 7, 1006–1014.Google Scholar

Zhong, S.; Macias, A. T.; MacKerell, A. D.. Computational identification of inhibitors of protein-protein interactions. Curr. Top. Med. Chem. 2007, 7, 63–82.Google Scholar

Sousa, S. F.; Fernandes, P. A.; Ramos, M. J.Protein-ligand docking: current status and future challenges. Proteins 2006, 65, 15–26.Google Scholar

Rester, U.Dock around the clock: current status of small molecule docking and scoring. QSAR Comb. Sci. 2006, 25, 605–615.Google Scholar

Coupez, B.; Lewis, R. A.Docking and scoring: theoretically easy, practically impossible?Curr. Med. Chem. 2006, 13, 2995–3003.Google Scholar

Mohan, V.; Gibbs, A. C.; Cummings, M. D.; Jaeger, E. P.; DesJarlais, R. L.Docking: successes and challenges. Curr. Pharm. Des. 2005, 11, 323–333.Google Scholar

Schulz-Gasch, T.; Stahl, M.Scoring functions for protein-ligand interactions: a critical perspective. Drug Disc. Today 2004, 1, 231–239.Google Scholar

Kitchen, D. B.; Decornez, H.; Furr, J. R.; Bajorath, J.Docking and scoring in virtual screening for drug discovery: methods and applications. Nat. Rev. Drug Discov. 2004, 3, 935–949.Google Scholar

Alvarez, J. C.High-throughput docking as a source of novel drug leads. Curr. Opin. Chem. Biol. 2004, 8, 365–370.Google Scholar

Muegge, I.; Enyedy, I. J.Virtual screening for kinase targets. Curr. Med. Chem. 2004, 11, 693–707.Google Scholar

Brooijmans, N.; Kuntz, I. D.Molecular recognition and docking algorithms. Annu. Rev. Biophys. Biomol. Struct. 2003, 335–373.Google Scholar

Glen, R. C.; Allen, S. C.Ligand-protein docking: cancer research at the interface between biology and chemistry. Curr. Med. Chem. 2003, 10, 763–777.Google Scholar

Taylor, R. D.; Jewsbury, P. J.; Essex, J. W.A review of protein-small molecule docking methods. J. Comput. Aided Mol. Des. 2002, 16, 151–166.Google Scholar

Lyne, P. D.Structure-based virtual screening: an overview. Drug Disc. Today 2002, 7, 1047–1055.Google Scholar

Shoichet, B. K.; McGovern, S. L.; Wei, B.; Irwin, J. J.Lead discovery using molecular docking. Curr. Opin. Chem. Biol. 2002, 6, 439–446.Google Scholar

Halperin, I.; Ma, B.; Wolfson, H.; Nussinov, R.Principles of docking: an overview of search algorithms and a guide to scoring functions. Proteins 2002, 47, 409–443.Google Scholar

Schneider, G.; Bohm, H. J.Virtual screening and fast automated docking methods. Drug Disc. Today 2002, 7, 64–70.Google Scholar

Abagyan, R.; Totrov, M.High-throughput docking for lead generation. Curr. Opin. Chem. Biol. 2001, 5, 375–382.Google Scholar

Sheridan, R. P.; McGaughey, G. B.; Cornell, W. D.Multiple protein structures and multiple ligands: effects on the apparent goodness of virtual screening results. J. Comput. Aided Mol. Des. 2008, 22, 257–265.Google Scholar

McGaughey, G. B.; Sheridan, R. P.; Bayly, C. I.; Culberson, J. C.; Kreatsoulas, C.; Lindsley, S.; Maiorov, V.; Truchon, J. F.; Cornell, W. D.Comparison of topological, shape, and docking methods in virtual screening. J. Chem. Inf. Model. 2007, 47, 1504–1519.Google Scholar

Cornell, W. D.Recent evaluations of high throughput docking methods for pharmaceutical lead finding: consensus and caveats. Annu. Rep. Comp. Chem. 2006, 2, 297–323.Google Scholar

Warren, G. L.; Andrews, C. W.; Capelli, A. M.; Clarke, B.; LaLonde, J.; Lambert, M. H.; Lindvall, M.; Nevins, N.; Semus, S. F.; Senger, S.; Tedesco, G.; Wall, I. D.; Woolven, J. M.; Peishoff, C. E.; Head, M. S.A critical assessment of docking programs and scoring functions. J. Med. Chem. 2006, 49, 5912–5931.Google Scholar

Cummings, M. D.; DesJarlais, R. L.; Gibbs, A. C.; Mohan, V.; Jaeger, E. P.Comparison of automated docking programs as virtual screening tools. J. Med. Chem. 2005, 48, 962–976.Google Scholar

Perola, E.; Walters, W. P.; Charifson, P. S.A detailed comparison of current docking and scoring methods on systems of pharmaceutical relevance. Proteins 2004, 56, 235–249.Google Scholar

Gilson, M. K.; Given, J. A.; Bush, B. L.; McCammon, J. A.The statistical-thermodynamic basis for computation of binding affinities: a critical review. Biophys. J. 1997, 72, 1047–1069.Google Scholar

Shirts, M. R.; Mobley, D. L.; Brown, S. P. Free energy calculations. In: Structure-Based Drug Design, Merz, K. M.; Ringe, D.; Reynolds, C. H., Eds. 2008, in press.

Chang, C. E.; Potter, M. J.; Gilson, M. K.Calculation of molecular configuration integrals. J. Phys. Chem. B 2003, 107, 1048–1055.Google Scholar

Kolossváry, I.Evaluation of the molecular configuration integral in all degrees of freedom for the direct calculation of conformational free energies: prediction of the anomeric free energy of monosaccharides. J. Phys. Chem. A 1997, 101(51), 9900–9905.Google Scholar

Head, M. S.; Given, J. A.; Gilson, M. K.Mining minima: direct computation of conformational free energy. J. Phys. Chem. A 1997, 101, 1609–1618.Google Scholar

Chang, C.-E.; Chen, W.; Gilson, M. K.Ligand configurational entropy and protein binding. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 1534–1539.Google Scholar

Kim, R.; Skolnick, J.Assessment of programs for ligand binding affinity prediction. J. Comp. Chem. 2008, 29, 1316–1331.Google Scholar

Manetti, F.; Falchi, F.; Crespan, E.; Schenone, S.; Maga, G.; Botta, M.N-(thiazol-2-yl)-2-thiophene carboxamide derivatives as Abl inhibitors identified by a pharmacophore-based database screening of commercially available compounds. Bioorg. Med. Chem. Lett. 2008, 18, 4328–4331.Google Scholar

Olsen, L.; Pettersson, I.; Hemmingsen, L.; Adolph, H.-W.; Jørgensen, F. S.Docking and scoring of metallo-β-lactamase inhibitors. J. Comput. Aided Mol. Des. 2004, 18, 287–302.Google Scholar

Holloway, M. K.; Wai, J. M.; Halgren, T. A.; Fitzgerald, P. M. D.; Vacca, J. P.; Dorsey, B. D.; Levin, R. B.; Thompson, W. J.; Chen, J.; deSolms, J.; Gaffin, N.; Ghosh, A. K.; Giuliani, E. A.; Graham, S. L.; Guare, J. P.; Hungate, R. W.; Lyle, T. A.; Sanders, W. M.; Tucker, T. J.; Wiggins, M.; Wiscount, C. M.; Woltersdorf, O. W.; Young, S. D.; Darke, P. L.; Zugay, J. A.A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site. J. Med. Chem. 1995, 38, 305–317.Google Scholar

http://www.rcsb.org/pdb/.

http://www.cas.org/products/scifindr/index.html.

http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed.

http://scholar.google.com/.

Herschhorn, A.; Hizi, A.Virtual screening, identification, and biochemical characterization of novel inhibitors of the reverse transcriptase of human immunodeficiency virus type-1. J. Med. Chem. 2008, 51, 5702–5713.Google Scholar

Park, H.; Bahn, Y. J.; Jung, S. K.; Jeong, D. G.; Lee, S.-H.; Seo, I.; Yoon, T.-S.; Kim, S. J.; Ryu, S. E.Discovery of novel Cdc25 phosphatase inhibitors with micromolar activity based on the structure-based virtual screening. J. Med. Chem. 2008, 51, 5533–5541.Google Scholar

Zhong, S.; Chen, X.; Zhu, X.; Dziegielewska, B.; Bachman, K. E.; Ellenberger, T.; Ballin, J. D.; Wilson, G. M.; Tomkinson, A. E.; MacKerell, A. D.. Identification and validation of human DNA ligase inhibitors using computer-aided drug design. J. Med. Chem. 2008, 51, 4553–4562.Google Scholar

Azim, M. K.; Ahmed, W.; Khan, I. A.; Rao, N. A.; Khan, K. M.Identification of acridinyl hydrazides as potent aspartic protease inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 3011–3015.Google Scholar

Pierce, A. C.; Jacobs, M.; Stuver-Moody, C.Docking study yields four novel inhibitors of the protooncogene Pim-1 kinase. J. Med. Chem. 2008, 51, 1972–1975.Google Scholar

Yang, H.; Dou, W.; Lou, J.; Leng, Y.; Shen, J.Discovery of novel inhibitors of 11β-hydroxysteroid dehydrogenase type 1 by docking and pharmacophore modeling. Bioorg. Med. Chem. Lett. 2008, 18, 1340–1345.Google Scholar

Dhagat, U.; Carbone, V.; Chung, R. P.-T.Matsunaga, T.; Endo, S.; Hara, A.; El-Kabbani, O.A salicylic acid-based analogue discovered from virtual screening as a potent inhibitor of human 20α-hydroxysteroid dehydrogenase. Med. Chem. 2007, 3, 546–550.Google Scholar

Knox, A. J. S.; Meegan, M. J.; Sobolev, V.; Frost, D.; Zisterer, D. M.; Williams, D. C.; Lloyd, D. G.Target specific virtual screening: optimization of an estrogen receptor screening platform. J. Med. Chem. 2007, 50, 5301–5310.Google Scholar

Cozza, G.; Bonvini, P.; Zorzi, E.; Poletto, G.; Pagano, M. A.; Sarno, S.; Donella-Deana, A.; Zagotto, G.; Rosolen, A.; Pinna, L. A.; Meggio, F.; Moro, S.Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application. J. Med. Chem. 2006, 49, 2363–2366.Google Scholar

Siedlecki, P.; Garcia Boy, R.; Musch, T.; Brueckner, B.; Suhai, S.; Lyko, F.; Zielenkiewicz, P.Discovery of two novel, small-molecule inhibitors of DNA methylation. J. Med. Chem. 2006, 49, 678–683.Google Scholar

Nolan, K. A.; Timson, D. J.; Stratford, I. J.; Bryce, R. A.In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg. Med. Chem. Lett. 2006, 16, 6246–6254.Google Scholar

Barril, X.; Brough, P.; Drysdale, M.; Hubbard, R. E.; Massey, A.; Surgenor, A.; Wright, L.Structure-based discovery of a new class of Hsp90 inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 5187–5191.Google Scholar

Zhao, L.; Brinton, R. D.Structure-based virtual screening for plant-based ERβ-selective ligands as potential preventative therapy against age-related neurodegenerative diseases. J. Med. Chem. 2005, 48, 3463–3466.Google Scholar

Mizutani, M. Y.; Itai, A.Efficient method for high-throughput virtual screening based on flexible docking: discovery of novel acetylcholinesterase inhibitors. J. Med. Chem. 2004, 47, 4818–4828.Google Scholar

Lyne, P. D.; Kenny, P. W.; Cosgrove, D. A.; Deng, C.; Zabludoff, S.; Wendoloski, J. J.; Ashwell, S.Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening. J. Med. Chem. 2004, 47, 1962–1968.Google Scholar

Rastelli, G.; Pacchioni, S.; Sirawaraporn, W.; Sirawaraporn, R.; Parenti, M. D.; Ferrari, A. M.Docking and database screening reveal new classes of Plasmodium falciparum dihydrofolate reductase inhibitors. J. Med. Chem. 2003, 46, 2834–2845.Google Scholar

Vangrevelinghe, E.; Zimmermann, K.; Schoepfer, J.; Portmann, R.; Fabbro, D.; Furet, P.Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput docking. J. Med. Chem. 2003, 46, 2656–2662.Google Scholar

Enyedy, I. J.; Lee, S.-L.; Kuo, A. H.; Dickson, R. B.; Lin, C.-L.; Wang, S.Structure-based approach for the discovery of bis-benzamidines as novel inhibitors of matriptase. J. Med. Chem. 2001, 44, 1349–1355.Google Scholar

Park, H.; Bahn, Y. J.; Jeong, D. G.; Woob, E. J.; Kwon, J. S.; Ryu, S. E.Identification of novel inhibitors of extracellular signal-regulated kinase 2 based on the structure-based virtual screening. Bioorg. Med. Chem. Lett. 2008, 18, 5372–5376.Google Scholar

Identification of BRAF inhibitors through in silico screening. J. Med. Chem. 2008, 51, 6121–6127.

Schlicker, C.; Rauch, A.; Hess, K. C.; Kachholz, B.; Levin, L. R.; Buck, J.; Steegborn, C.Structure-based development of novel adenylyl cyclase inhibitors. J. Med. Chem. 2008, 51, 4456–4464.Google Scholar

Park, H.; Jung, S.-K.; Jeong, D. G.; Ryu, S. E.; Kim, S. J.Discovery of VHR phosphatase inhibitors with micromolar activity based on structure-based virtual screening. ChemMedChem 2008, 3, 880–887.Google Scholar

Corbeil, C. R.; Englebienne, P.; Yannopoulos, C. G.; Chan, L.; Das, S. K.; Bilimoria, D.; L'Heureux, L.; Moitessier, N.Docking ligands into flexible and solvated macromolecules. 2. Development and application of FITTED 1.5 to the virtual screening of potential HCV polymerase inhibitors. J. Chem. Inf. Model. 2008, 48, 902–909.Google Scholar

Kolb, P.; Huang, D.; Dey, F.; Caflisch, A.Discovery of kinase inhibitors by high-throughput docking and scoring based on a transferable linear interaction energy model. J. Med. Chem. 2008, 51, 1179–1188.Google Scholar

Salam, N. K.; Huang, T. H-W.; Kota, B. P.; Kim, M. S.; Li, Y.; Hibbs, D. E.Novel PPAR-gamma agonists identified from a natural product library: a virtual screening, induced-fit docking and biological assay study. Chem. Biol. Drug Des. 2008, 71, 57–70.Google Scholar

Katritch, V.; Byrd, C. M.; Tseitin, V.; Dai, D.; Raush, E.; Totrov, M.; Abagyan, R.; Jordan, R.; Hruby, D. E.Discovery of small molecule inhibitors of ubiquitin-like poxvirus proteinase I7L using homology modeling and covalent docking approaches. J. Comput. Aided Mol. Des. 2007, 21, 549–558.Google Scholar

Hu, X.; Prehna, G.; Stebbins, C. E.Targeting plague virulence factors: a combined machine learning method and multiple conformational virtual screening for the discovery of Yersinia protein kinase A inhibitors. J. Med. Chem. 2007, 50, 3980–3983.Google Scholar

Rummey, C.; Nordhoff, S.; Thiemannc, M.; Metz, G.In silico fragment-based discovery of DPP-IV S1 pocket binders. Bioorg. Med. Chem. Lett. 2006, 16, 1405–1409.Google Scholar

Irwin, J. J.; Raushel, F. M.; Shoichet, B. K.Virtual screening against metalloenzymes for inhibitors and substrates. Biochemistry 2005, 44, 12316–12328.Google Scholar

Hancock, C. N.; Macias, A.; Lee, E. K.; Yu, S. Y.; MacKerell, A. D.; Shapiro, P.Identification of novel extracellular signal-regulated kinase docking domain inhibitors. J. Med. Chem. 2005, 48, 4586–4595.Google Scholar

Toledo-Sherman, L.; Deretey, E.; Slon-Usakiewicz, J. J.; Ng, W.; Dai, J.-R.; Estelle Foster, J.; Redden, P. R.; Uger, M. D.; Liao, L. C.; Pasternak, A.; Reid, N.Frontal affinity chromatography with MS detection of EphB2 tyrosine kinase receptor. 2. Identification of small-molecule inhibitors via coupling with virtual screening. J. Med. Chem. 2005, 48, 3221–3230.Google Scholar

Forino, M.; Jung, D.; Easton, J. B.; Houghton, P. J.; Pellecchia, M.Virtual docking approaches to protein kinase B inhibition. J. Med. Chem. 2005, 48, 2278–2281.Google Scholar

Mozziconacci, J.-C.; Arnoult, E.; Bernard, P.; Do, Q. T.; Marot, C.; Morin-Allory, L.Optimization and validation of a docking-scoring protocol and application to virtual screening for COX-2 inhibitors. J. Med. Chem. 2005, 48, 1055–1068.Google Scholar

Chen, L.; Gui, C.; Luo, X.; Yang, Q.; Guenther, S.; Scandella, E.; Drosten, C.; Bai, D.; He, X.; Ludewig, B.; Chen, J.; Luo, H.; Yang, Y.; Yang, Y.; Zou, J.; Thiel, V.; Chen, K.; Shen, J.; Shen, X.; Jiang, H.Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro. J. Virol. 2005, 79, 7095–7103.Google Scholar

Li, C.; Xu, L.; Wolan, D. W.; Wilson, I. A.; Olson, A. J.Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of Autodock to identify novel nonfolate inhibitors. J. Med. Chem. 2004, 47, 6681–6690.Google Scholar

Ferrari, A. M.; Wei, B. Q.; Costantino, L.; Shoichet, B. K.Soft docking and multiple receptor conformations in virtual screening. J. Med. Chem. 2004, 47, 5076–5084.Google Scholar

Thurmond, R. L.; Beavers, M. P.; Cai, H.; Meduna, S. P.; Gustin, D. J.; Sun, S.; Almond, H. J.; Karlsson, L.; Edwards, J. P.Nonpeptidic, noncovalent inhibitors of the cysteine protease cathepsin S. J. Med. Chem. 2004, 47, 4799–4801.Google Scholar

Schapira, M.; Raaka, B. M.; Das, S.; Fan, L.; Totrov, M.; Zhou, Z.; Wilson, S. R.; Abagyan, R.; Samuels, H. H.Discovery of diverse thyroid hormone receptor anagonists by high-throughput docking. Proc. Natl. Acad. Sci. USA 2003, 100, 7354–7359.Google Scholar

Wu, S. Y.; McNae, I.; Kontopidis, G.; McClue, S. J.; McInnes, C.; Stewart, K. J.; Wang, S.; Zheleva, D. I.; Marriage, H.; Lane, D. P.; Taylor, P.; Fischer, P. M.; Walkinshaw, M. D.Discovery of a novel family of CDK inhibitors with the program LIDAEUS structural basis for ligand-induced disordering of the activation loop. Structure 2003, 11, 399–410.Google Scholar

Liu, H.; Li, Y.; Song, M.; Tan, X.; Cheng, F.; Zheng, S.; Shen, J.; Luo, X.; Ji, R.; Yue, J.; Hu, G.; Jiang, H.; Chen, K.Structure-based discovery of potassium channel blockers from natural products: virtual screening and electrophysiological assay testing. Chemistry 2003, 10, 1103–1113.Google Scholar

Doman, T. N.; McGovern, S. L.; Witherbee, B. J.; Kasten, T. P.; Kurumbail, R.; Stallings, W. C.; Connolly, D. T.; Shoicht, B. K.Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. J. Med. Chem. 2002, 45, 2213–2221.Google Scholar

Paiva, A. M.; Vanderwall, D. E.; Blanchard, J. S.; Kozarich, J. W.; Williamson, J. M.; Kelly, T. M.Inhibitors of dihydropicolinate reductase, a key enzyme of the diaminopimelate pathway of Mycobacterium tuberculosis. Biochim. Biophys. Acta 2001, 1545, 67–77.Google Scholar

Enyedy, I. J.; Ling, Y.; Nacro, K.; Tomita, Y.; Wu, X.; Cao, Y.; Guo, R.; Li, B.; Zhu, X.; Huang, Y.; Long, Y.-Q.; Roller, P. P.; Yang, D.; Wang, S.Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J. Med. Chem. 2001, 44, 4313–4234.Google Scholar

Iwata, Y.; Arisawa, M.; Hamada, R.; Kita, Y.; Mizutani, M. Y.; Tomioka, N.; Itai, A.; Miyamoto, S.Discovery of novel aldose reductase inhibitors using a protein structure-based approach: 3D-database search followed by design and synthesis. J. Med. Chem. 2001, 44, 1718–1728.Google Scholar

Gradler, U.; Gerber, H.-D.; Goodenough-Lashua, D. A. M.; Garcia, G. A.; Ficner, R.; Reuter, K.; Stubbs, M. T.; Klebe, G.A new target for shigellosis: rational design and crystallographic studies of inhibitors of tRNA-guanine transglycosylase. J. Mol. Biol. 2001, 306, 455–467.Google Scholar

Pang, Y.-P.; Xub, K.; Kollmeyer, T. M.; Perola, E.; McGrathe, W. J.; Greene, D. T.; Mangele, W. F.Discovery of a new inhibitor lead of adenovirus proteinase: steps toward selective, irreversible inhibitors of cysteine proteinases. FEBS Lett. 2001, 502, 93–97.Google Scholar

Hopkins, S. C.; Vale, R. D.; Kuntz, I. D.Inhibitors of kinesin activity from structure-based computer screening. Biochemistry 2000, 39, 2805–2814.Google Scholar

Freymann, D. M.; Wenck, M. A.; Engel, J. C.; Feng, J.; Focia, P. J.; Eakin, A. E.; Craig, S. P.. Efficient identification of inhibitors targeting the closed active site conformation of the HPRT from Trypanosoma cruzi. Chem. Biol. 2000, 7, 957–968.Google Scholar

Wang, J.-L.; Liu, D.; Zhang, Z.-J.; Shan, S.; Han, X.; Srinivasula, S. M.; Croce, C. M.; Alnemri, E. S.; Huang, Z.Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl. Acad. Sci. USA 2000, 97, 7124–7129.Google Scholar

Liu, J.-S.; Cheng, W.-C.; Wang, H.-J.; Chen, Y.-C.; Wang, W.-C.Structure-based inhibitor discovery of Helicobacter pylori dehydroquinate synthase. Biochem. Biophys. Res. Commun. 2008, 373, 1–7.Google Scholar

Mukherjee, P.; Desai, P.; Ross, L.; White, E. L.; Avery, M. A.Structure-based virtual screening against SARS-3CLpro to identify novel non-peptidic hits. Bioorg. Med. Chem. 2008, 16, 4138–4149.Google Scholar

Park, H.; Jung, S.-K.; Jeong, D. G.; Ryu, S. E.; Kim, S. J.Discovery of novel PRL-3 inhibitors based on the structure-based virtual screening. Bioorg. Med. Chem. Lett. 2008, 18, 2250–2255.Google Scholar

Ruiz, F. M.; Gil-Redondo, R.; Morreale, A.; Ortiz, A. R.; Fabrega, C.; Bravo, J.Structure-based discovery of novel non-nucleosidic DNA alkyltransferase inhibitors: virtual screening and in vitro and in vivo activities. J. Chem. Inf. Model. 2008, 48, 844–854.Google Scholar

Babaoglu, K.; Simeonov, A.; Irwin, J. J.; Nelson, M. E.; Feng, B.; Thomas, C. J.; Cancian, L.; Costi, M. P.; Maltby, D. A.; Jadhav, A.; Inglese, J.; Austin, C. P.; Shoichet, B. K.Comprehensive mechanistic analysis of hits from high-throughput and docking screens against β-lactamase. J. Med. Chem. 2008, 51, 2502–2511.Google Scholar

Park, H.; Hwang, K. Y.; Oh, K. H.; Kim, Y. H.; Lee, J. Y.; Kim, K.Discovery of novel α-glucosidase inhibitors based on the virtual screening with the homology-modeled protein structure. Bioorg. Med. Chem. 2008, 16, 284–292.Google Scholar

Montes, M.; Braud, E.; Miteva, M. A.; Goddard, M.-L.; Mondesert, O.; Kolb, S.; Brun, M.-P.; Ducommun, B.; Garbay, C.; Villoutreix, B. O.Receptor-based virtual ligand screening for the identification of novel CDC25 phosphatase inhibitors. J. Chem. Inf. Model. 2008, 48, 157–165.Google Scholar

Agarwal, S. M.; Jain, R.; Bhattacharya, A.; Azam, A.Inhibitors of Escherichia coli serine acetyltransferase block proliferation of Entamoeba histolytica trophozoites. Int. J. Parasitol. 2008, 38, 137–141.Google Scholar

Hellmuth, K.; Grosskopf, S.; Lum, C. T.; Wuertele, M.; Roeder, N.; Kries, J. P.; Rosario, M.; Rademann, J.; Birchmeier, W.Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking. Proc. Natl. Acad. Sci. USA 2008, 105, 7275–7280.Google Scholar

Betzi, S.; Restouin, A.; Opi, S.; Arold, S. T.; Parrot, I.; Guerlesquin, F.; Morelli, X.; Collette, Y.Protein-protein interaction inhibition (2P2I) combining high throughput and virtual screening: application to the HIV-1 nef protein. Proc. Natl. Acad. Sci. USA 2007, 104, 19256–19261.Google Scholar

Wang, G.; Huang, N.; Meng, Z.; Liu, Q.Identification of novel inhibitors of the streptogramin group A acetyltransferase via virtual screening. Yaoxue Xuebao 2007, 42, 47–53.Google Scholar

Luzhkov, V. B.; Selisko, B.; Nordqvist, A.; Peyrane, F.; Decroly, E.; Alvarez, K.; Karlen, A.; Canard, B.; Aaqvist, J.Virtual screening and bioassay study of novel inhibitors for dengue virus mRNA cap (nucleoside-2′O)-methyltransferase. Bioorg. Med. Chem. 2007, 15, 7795–7802.Google Scholar

Ragno, R.; Mai, A.; Simeoni, S.; Caroli, A.; Caffarelli, E.; Neve, P.; Gioia, U.; Bozzoni, I.Structure-based drug discovery of XendoU inhibitors through multi-docking virtual screening. In: Frontiers in CNS and Oncology Medicinal Chemistry, Vol. COMC-063. Washington, DC: American Chemical Society; 2007.

Park, H.; Kim, Y.-J.; Hahn, J.-S.A novel class of Hsp90 inhibitors isolated by structure-based virtual screening. Bioorg. Med. Chem. Lett. 2007, 17, 6345–6349.Google Scholar

Ostrov, D. A.; Hernandez Prada, J. A.; Corsino, P. E.; Finton, K. A.; Le, N.; Rowe, T. C.Discovery of novel DNA gyrase inhibitors by high-throughput virtual screening. Antibac. Agents Chemother. 2007, 51, 3688–3698.Google Scholar

Szewczuk, L. M.; Saldanha, S. A.; Ganguly, S.; Bowers, E. M.; Javoroncov, M.; Karanam, B.; Culhane, J. C.; Holbert, M. A.; Klein, D. C.; Abagyan, R.; Cole, P. A.De novo discovery of serotonin N-acetyltransferase inhibitors. J. Med. Chem. 2007, 50, 5330–5338.Google Scholar

Liao, C.; Karki, R. G.; Marchand, C.; Pommier, Y.; Nicklaus, M. C.Virtual screening application of a model of full-length HIV-1 integrase complexed with viral DNA. Bioorg. Med. Chem. Lett. 2007, 17, 5361–5365.Google Scholar

Srivastava, S. K.; Dube, D.; Kukshal, V.; Jha, A. K.; Hajela, K.; Ramachandran, R.NAD+-dependent DNA ligase (Rv3014c) from Mycobacterium tuberculosis: novel structure-function relationship and identification of a specific inhibitor. Proteins 2007, 69, 97–111.Google Scholar

Brooks, W. H.; McCloskey, D. E.; Daniel, K. G.; Ealick, S. E.; III; Secrist, , J. A.; Waud, W. R.; Pegg, A. E.; Guida, W. C.In silico chemical library screening and experimental validation of a novel 9-aminoacridine based lead-inhibitor of human S-adenosylmethionine decarboxylase. J. Chem. Inf. Model. 2007, 47, 1897–1905.Google Scholar

Spannhoff, A.; Machmur, R.; Heinke, R.; Trojer, P.; Bauer, I.; Brosch, G.; Schuele, R.; Hanefeld, W.; Sippl, W.; Jung, M.A novel arginine methyltransferase inhibitor with cellular activity. Bioorg. Med. Chem. Lett. 2007, 17, 4150–4153.Google Scholar

Wang, J.-G.; Xiao, Y.-J.; Li, Y.-H.; Ma, Y.; Li, Z.-M.Identification of some novel AHAS inhibitors via molecular docking and virtual screening approach. Bioorg. Med. Chem. 2007, 15, 374–380.Google Scholar

Hamilton, D.; Wu, J. H.; Batist, G.Structure-based identification of novel human γ-glutamylcysteine synthetase inhibitors. Mol. Pharm. 2007, 71, 1140–1147.Google Scholar

Tsai, K.-C.; Chen, S.-Y.; Liang, P.-H.; Lu, I.-L.; Mahindroo, N.; Hsieh, H.-P.; Chao, Y.-S.; Liu, L.; Liu, D.; Lien, W.; Lin, T.-H.; Wu, S.-Y.Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies. J. Med. Chem. 2006, 49, 3485–3495.Google Scholar

Cavasotto, C. N.; Ortiz, M. A.; Abagyan, R. A.; Piedrafita, F. J.In silico identification of novel EGFR inhibitors with antiproliferative activity against cancer cells. Bioorg. Med. Chem. Lett. 2006, 16, 1969–1974.Google Scholar

Dooley, A. J.; Shindo, N.; Taggart, B.; Park, J-.G.; Pang, Y-.P.From genome to drug lead: identification of a small-molecule inhibitor of the SARS virus. Bioorg. Med. Chem. Lett. 2006, 16, 830–833.Google Scholar

Prykhod'ko, A. O.; Yakovenko, O. Y.; Golub, A. G.; Bdzhola, V. G.; Yarmoluk, S. M.Evaluation of 4H-4-chromenone derivatives as inhibitors of protein kinase CCK. Biopolimeri i Klitina 2005, 21, 287–292.Google Scholar

Huang, D.; Lüthi, U.; Kolb, P.; Edler, K.; Cecchini, M.; Audetat, S.; Barberis, A.; Caflisch, A.Discovery of cell-permeable nonpeptide inhibitors of β-secretase by high-throughput docking and continuum electrostatics calculations. J. Med. Chem. 2005, 48, 5108–5111.Google Scholar

Liu, Z.; Huang, C.; Fan, K.; Wei, P.; Chen, H.; Liu, S.; Pei, J.; Shi, L.; Li, B.; Yang, K.; Liu, Y.; Lai, L.Virtual screening of novel noncovalent inhibitors for SARS-CoV 3C-like proteinase. J. Chem. Inf. Model. 2005, 45, 10–17.Google Scholar

Soelaiman, S.; Wei, B. Q.; Bergson, P.; Lee, Y.-S.; Shen, Y.; Mrksich, M.; Shoichet, B. K.; Tang, W.-J.Structure-based inhibitor discovery against adenylyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough. J. Biol. Chem. 2003, 278, 25990–25997.Google Scholar

McNally, V. A.; Gbaj, A.; Douglas, K. T.; Stratford, I. J.; Jaffar, M.; Freemanan, S.; Bryce, R. A.Identification of a novel class of inhibitor of human and Escherichia coli thymidine phosphorylase by in silico screening. Bioorg. Med. Chem. Lett. 2003, 13, 3705–3709.Google Scholar

Peng, H.; Huang, N.; Qi, J.; Xie, P.; Xu, C.; Wang, J.; Yang, C.Identification of novel inhibitors of BCR-Abl tyrosine kinase via virtual screening. Bioorg. Med. Chem. Lett. 2003, 13, 3693–3699.Google Scholar

Pickett, S. D.; Sherborne, B. S.; Wilkinson, T.; Bennett, J.; Borkakoti, N.; Broadhurst, M.; Hurst, D.; Kilford, I.; McKinnell, M.; Jones, P. S.Discovery of novel low molecular weight inhibitors of IMPDH via virtual needle screening. Bioorg. Med. Chem. Lett. 2003, 13, 1691–1694.Google Scholar

Powers, R. A.; Morandi, F.; Shoichet, B. K.Structure-based discovery of a novel, noncovalent inhibitor of AmpC β-lactamase. Structure 2002, 10, 1013–1023.Google Scholar

Kamionka, M.; Rehm, T.; Beisel, H.-G.; Lang, K.; Engh, R. A.; Holak, T. A.In silico and NMR identification of inhibitors of the IGF-I and IGF-Binding Protein-5 interaction. J. Med. Chem. 2002, 45, 5655–5660.Google Scholar

Iino, M.; Furugori, T.; Mori, T.; Moriyama, S.; Fukuzawa, A.; Shibano, T.Rational design and evaluation of new lead compound structures for selective βARK1 inhibitors. J. Med. Chem. 2002, 45, 2150–2159.Google Scholar

Perola, E.; Xu, K.; Kollmeyer, T. M.; Kaufmann, S. H.; Prendergast, F. G.; Pang, Y.-P.Successful virtual screening of a chemical database for farnesyltransferase inhibitor leads. J. Med. Chem. 2000, 43, 401–408.Google Scholar

Sarmiento, M.; Wu, L.; Keng, Y.-F.; Song, L.; Luo, Z.; Huang, Z.; Wu, G.-Z.; Yuan, A. K.; Zhang, Z.-Y.Structure-based discovery of small molecule inhibitors targeted to protein tyrosine phosphatase 1B. J. Med. Chem. 2000, 43, 146–155.Google Scholar

Nordqvist, A.; Nilsson, M. T.; Roettger, S.; Odell, L. R.; Krajewski, W. W.; Andersson, C. E.; Larhed, M.; Mowbray, S. L.; Karlen, A.Evaluation of the amino acid binding site of Mycobacterium tuberculosis glutamine synthetase for drug discovery. Bioorg. Med. Chem. 2008, 16, 5501–5513.Google Scholar

Feder, M.; Purta, E.; Koscinski, L.; Cubrilo, S.; Vlahovicek, G. M.; Bujnicki, J. M.Virtual screening and experimental verification to identify potential inhibitors of the ErmC methyltransferase responsible for bacterial resistance against macrolide antibiotics. ChemMedChem 2008, 3, 316–322.Google Scholar

Zeng, Z.; Qian, L.; Cao, L.; Tan, H.; Huang, Y.; Xue, X.; Shen, Y.; Zhou, S.Virtual screening for novel quorum sensing inhibitors to eradicate biofilm formation of Pseudomonas aeruginosa. App. Microbiol. Biotechnol. 2008, 79, 119–126.Google Scholar

Kuo, C.-J.; Guo, R.-T.; Lu, I.-L.; Liu, H. G.; Wu, S.-Y.; Ko, T.-P.; Wang, A. H.-J.; Liang, P.-H.Structure-based inhibitors exhibit differential activities against Helicobacter pylori and Escherichia coli undecaprenyl pyrophosphate synthases. J. Biomed. Biotechnol. 2008.Google Scholar

Hirayama, K.; Aoki, S.; Nishikawa, K.; Matsumoto, T.; Wada, K.Identification of novel chemical inhibitors for ubiquitin C-terminal hydrolase-L3 by virtual screening. Bioorg. Med. Chem. 2007, 15, 6810–6818.Google Scholar

Song, H.; Wang, R.; Wang, S.; Lin, J.A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc. Natl. Acad. Sci. USA 2005, 102, 4700–4705.Google Scholar

Westerfors, M.; Tedebark, U.; Andersson, H. O.; Öhrman, S.; Choudhury, D.; Ersoy, O.; Shinohara, Y.; Axén, A.; Carredano, E.; Baumann, H.Structure-based discovery of a new affinity ligand to pancreatic α-amylase. J. Mol. Recognit. 2003, 16, 396–405.Google Scholar

Chowdhury, S. F.; Lucrezia, R. D.; Guerrero, R. H.; Brun, R.; Goodman, J.; Ruiz-Perez, L. M.; Pacanowska, D. G.; Gilbert, I. H.Novel inhibitors of leishmanial dihydrofolate reductase. Bioorg. Med. Chem. Lett. 2001, 11, 977–980.Google Scholar

Malvezzi, A.; Rezende, L.; Izidoro, M. A.; Cezari, M. H. S.; Juliano, L.; Amaral, A. T.Uncovering false positives on a virtual screening search for cruzain inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 350–354.Google Scholar

Barreiro, G.; Guimaraes, C. R. W.; Tubert-Brohman, I.; Lyons, T. M.; Tirado-Rives, J.; Jorgensen, W. L.Search for non-nucleoside inhibitors of HIV-1 reverse transcriptase using chemical similarity, molecular docking, and MM-GB/SA scoring. J. Chem. Inf. Model. 2007, 47, 2416–2428.Google Scholar

Brenk, R.; Irwin, J. J.; Shoichet, B. K.Here be dragons: docking and screening in an uncharted region of chemical space. J. Biomol. Screen. 2005, 10, 667–674.Google Scholar

Kanji., G. K.100 Statistical Tests, 3rd edition. Thousand Oaks, CA: Sage, 2006.

http://stattrek.com/Tables/ChiSquare.aspx.

Snedecor, G. W.; Cochran., W. G.Statistical Methods, 8th edition. Ames, IA: Iowa State University Press; 1989, 135–148.

Irwin, J. J.Shoichet, B. K.ZINC – a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model. 2005, 45, 177–182.Google Scholar

Negron-Encarnacion, I.; Arce, R.; Jimenez, M.Characterization of acridine species adsorbed on (NH4)2SO4, SiO2, Al2O3, and MgO by steady-state and time-resolved fluorescence and diffuse reflectance techniques. J. Phys. Chem. A 2005, 109, 787–797.Google Scholar

Turek-Etienne, T. C.; Small, E. C.; Soh, S. C.; Xin, T. A.; Gaitonde, P. V.; Barrabee, E. B.; Hart, R. F.; Bryant, R. W.Evaluation of fluorescent compound interference in 4 fluorescence polarization assays: 2 kinases, 1 protease, and 1 phosphatase. J. Biomol. Screening 2003, 8, 176–184.Google Scholar

Feng, B. Y.; Simeonov, A.; Jadhav, A.; Babaoglu, K.; Inglese, J.; Shoichet, B. K.; Austin, C. P.A high-throughput screen for aggregation-based inhibition in a large compound library. J. Med. Chem. 2007, 50, 2385–2390.Google Scholar

Mojumdar, S. C.; Martiska, L.; Valigura, D.; Melnik, M.Thermal and spectral properties of halogenosalicylato-Cu(II) complexes. J. Therm. Analysis and Calor. 2003, 74, 905–914.Google Scholar

Schwarz, K. B.; Arey, B. J.; Tolman, K.; Mahanty, S.Iron chelation as a possible mechanism for aspirin-induced malondialdehyde production by mouse liver microsomes and mitochondria. J. Clin. Invest. 1988, 81, 165–170.Google Scholar

Ha, S.; Andreani, R.; Robbins, A.; Muegge, I.Evaluation of docking/scoring approaches: a comparative study based on MMP3 inhibitors. J. Comput. Aided Mol. Design 2000, 14, 435–448.Google Scholar

http://sampl.eyesopen.com/.

Goto, J.; Kataoka, R.; Hirayama, N.Ph4Dock: pharmacophore-based protein-ligand docking. J. Med. Chem. 2004, 47, 6804–6811.Google Scholar

Blow, D. M.A rearrangement of Cruickshanks formulae for the diffraction-component precision index. Acta Crystallogr., Sect. D 2002, D58, 792–797.Google Scholar

Cruickshank, D. W. J.Remarks about protein structure precision. Acta Crystallogr., Sect. D 1999, D55, 583–601.Google Scholar

http://www.eyesopen.com/products/applications/omega.html.

http://www.eyesopen.com/products/applications/rocs.html.

Bohacek, R. S.; McMartin, C.Definition and display of steric, hydrophobic, and hydrogen-bonding properties of ligand binding sites in proteins using Lee and Richards accessible surface: validation of a high-resolution graphical tool for drug design. J. Med. Chem. 1992, 35, 1671–1684.Google Scholar

Wang, Z.; Canagarajah, B. J.; Boehm, J. C.; Kassisà, S.; Cobb, M. H.; Young, P. R.; Abdel-Meguid, S.; Adams, J. L.; Goldsmith, E. J.Structural basis of inhibitor selectivity in MAP kinases. Structure 1998, 6, 1117–1128.Google Scholar

Hare, B. J.; Walters, W. P.; Caron, P. R.; Bemis, G. W.CORES: An automated method for generating three-dimensional models of protein/ligand complexes. J. Med. Chem. 2004, 47, 4731–4740.Google Scholar

http://www.bioinform.com/issues/12_41/features/150096-1.html.

Accessibility standard: Unknown

Why this information is here

This section outlines the accessibility features of this content - including support for screen readers, full keyboard navigation and high-contrast display options. This may not be relevant for you.

Accessibility Information

Accessibility compliance for the PDF of this chapter is currently unknown and may be updated in the future.